Segmental versus Extended Resection for Colon Cancer in Lynch Syndrome

Abstract

Lynch's syndrome is a common cause of hereditary colorectal cancer (CRC), resulting in higher risk of CRC and development of subsequent, metachronous CRC (mCRC). Beyond treating the primary cancer, surgeons and patients must decide on whether performing an extended colectomy, to reduce the risk of mCRC, is worth the change in function that comes with the larger operation. Considerations include likelihood for mCRC, morbidity and quality of life after resection, impact of pathogenic variant, and certain other cancer risk reduction options. The contemporary evidence to guide these decisions is reviewed herein.

Keywords

colon cancer - Lynch's syndrome - mismatch repair - colectomy - cancer surveillance

Publikationsverlauf

Artikel online veröffentlicht:
10. Januar 2025

• References

• 1 Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin 2023; 73 (03) 233-254
• 2 Peltomäki P, Nyström M, Mecklin JP, Seppälä TT. Lynch syndrome genetics and clinical implications. Gastroenterology 2023; 164 (05) 783-799
• 3 Sinicrope FA. Lynch syndrome–associated colorectal cancer. N Engl J Med 2018; 379 (08) 764-773
• 4 Olave MC, Graham RP. Mismatch repair deficiency: the what, how and why it is important. Genes Chromosomes Cancer 2022; 61 (06) 314-321
• 5 Kim TJ, Kim ER, Hong SN. et al. Survival outcome and risk of metachronous colorectal cancer after surgery in Lynch syndrome. Ann Surg Oncol 2017; 24 (04) 1085-1092
• 6 Parry S, Win AK, Parry B. et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60 (07) 950-957
• 7 Renkonen-Sinisalo L, Seppälä TT, Järvinen HJ, Mecklin JP. Subtotal colectomy for colon cancer reduces the need for subsequent surgery in Lynch syndrome. Dis Colon Rectum 2017; 60 (08) 792-799
• 8 Andresdottir AK, Einarsson H, Jonsdottir H, Jonasson JG, Bjornsson ES, Haraldsdottir S. Metachronous colorectal cancer in Icelandic MSH6 and PMS2 Lynch syndrome carriers in 1955–2017: a population-based study. Gastroenterology 2023; 164 (07) 1314-1316.e1
• 9 Kalady MF, McGannon E, Vogel JD, Manilich E, Fazio VW, Church JM. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. Ann Surg 2010; 252 (03) 507-513
• 10 Natarajan N, Watson P, Silva-Lopez E, Lynch HT. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum 2010; 53 (01) 77-82
• 11 Aronson M, Holter S, Semotiuk K. et al. DNA mismatch repair status predicts need for future colorectal surgery for metachronous neoplasms in young individuals undergoing colorectal cancer resection. Dis Colon Rectum 2015; 58 (07) 645-652
• 12 Cirillo L, Urso ED, Parrinello G. et al. High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria. . Ann Surg 2013; 257 (05) 900-904
• 13 Win AK, Parry S, Parry B. et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol 2013; 20 (06) 1829-1836
• 14 Stupart DA, Goldberg PA, Baigrie RJ, Algar U, Ramesar R. Surgery for colonic cancer in HNPCC: total vs segmental colectomy. Colorectal Dis 2011; 13 (12) 1395-1399
• 15 Herzig DO, Buie WD, Weiser MR. et al. Clinical practice guidelines for the surgical treatment of patients with Lynch syndrome. Dis Colon Rectum 2017; 60 (02) 137-143
• 16 You YN, Chua HK, Nelson H, Hassan I, Barnes SA, Harrington J. Segmental vs. extended colectomy: measurable differences in morbidity, function, and quality of life. Dis Colon Rectum 2008; 51 (07) 1036-1043
• 17 Haanstra JF, Gopie JP. et al. Quality of life after surgery for colon cancer in patients: diseases of the colon & rectum. Dis Colon Rectum 2012; 55 (06) 653-659
• 18 Urso EDL, Celotto F, Giandomenico F. et al. Analysis of morbidity and mortality, quality of life and bowel function after total colectomy with ileorectal anastomosis versus right and left hemicolectomy: a study to optimise the treatment of lynch syndrome and attenuated polyposis coli. Eur J Surg Oncol 2020; 46 (09) 1613-1619
• 19 Sun J, Dong M, Xiao X. Efficacy, functional outcome and post-operative complications of total abdominal colectomy with ileorectal anastomosis vs. segmental colectomy in hereditary non-polyposis colorectal cancer. Exp Ther Med 2018; 16 (03) 1603-1612
• 20 Nagasaki T, Arai M, Chino A, Akiyoshi T, Fukunaga Y, Ueno M. Feasibility of segmental colectomy followed by endoscopic surveillance as a treatment strategy for colorectal cancer patients with Lynch syndrome. Dig Surg 2018; 35 (05) 448-456
• 21 Møller P, Seppälä T, Bernstein I. et al; Mallorca Group. http://mallorca-group.eu ). Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 2017; 66 (03) 464-472
• 22 Møller P, Seppälä TT, Bernstein I. et al; Mallorca Group. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 2018; 67 (07) 1306-1316
• 23 Eikenboom EL, Moen S, van Leerdam ME. et al; collaborative investigators from the Dutch Foundation for Detection of Hereditary Tumors. Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study. Lancet Gastroenterol Hepatol 2023; 8 (12) 1106-1117
• 24 Quezada-Diaz FF, Hameed I, von Mueffling A. et al. Risk of metachronous colorectal neoplasm after a segmental colectomy in Lynch syndrome patients according to mismatch repair gene status. J Am Coll Surg 2020; 230 (04) 669-675
• 25 Malik SS, Lythgoe MP, McPhail M, Monahan KJ. Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. Fam Cancer 2018; 17 (04) 557-564
• 26 Seppala TT, Latchford A, Negoi I. et al. European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. Br J Surg 2021; 108 (05) 484-498
• 27 Serrano D, Patrignani P, Stigliano V. et al. Aspirin colorectal cancer prevention in Lynch syndrome: recommendations in the era of precision medicine. Genes (Basel) 2022; 13 (03) 460
• 28 Burn J, Gerdes AM, Macrae F. et al; CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378 (9809) 2081-2087
• 29 Movahedi M, Bishop DT, Macrae F. et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study. J Clin Oncol 2015; 33 (31) 3591-3597
• 30 Reyes-Uribe L, Wu W, Gelincik O. et al. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut 2021; 70 (03) 555-566
• 31 Bowen CM, Deng N, Reyes-Uribe L. et al. Naproxen chemoprevention induces proliferation of cytotoxic lymphocytes in Lynch syndrome colorectal mucosa. Front Immunol 2023; 14: 1162669
• 32 Bolivar AM, Duzagac F, Sinha KM, Vilar E. Advances in vaccine development for cancer prevention and treatment in Lynch syndrome. Mol Aspects Med 2023; 93: 101204
• 33 Sei S, Ahadova A, Keskin DB. et al. Lynch syndrome cancer vaccines: a roadmap for the development of precision immunoprevention strategies. Front Oncol 2023; 13: 1147590
• 34 Gebert J, Gelincik O, Oezcan-Wahlbrink M. et al. Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model. Gastroenterology 2021; 161 (04) 1288-1302.e13
• 35 Solomon A, Alteber Z, Bassan D. et al. On the development of a neoantigen vaccine for the prevention of Lynch syndrome. Int J Cancer 2022; 151 (01) 107-119
• 36 D'Alise AM, Brasu N, De Intinis C. et al. Adenoviral-based vaccine promotes neoantigen-specific CD8⁺ T cell stemness and tumor rejection. Sci Transl Med 2022; 14 (657) eabo7604
• 37 Chen G, Jin Y, Guan WL. et al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol 2023; 8 (05) 422-431
• 38 Ahadova A, Seppälä TT, Engel C. et al. The “unnatural” history of colorectal cancer in Lynch syndrome: lessons from colonoscopy surveillance. Int J Cancer 2021; 148 (04) 800-811